Compare AERT & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AERT | SCYX |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 24.6M |
| IPO Year | N/A | 2014 |
| Metric | AERT | SCYX |
|---|---|---|
| Price | $0.56 | $0.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 181.3K | ★ 561.5K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,346,000.00 | $2,932,000.00 |
| Revenue This Year | N/A | $167.73 |
| Revenue Next Year | N/A | $290.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.46 | $0.57 |
| 52 Week High | $2.67 | $1.49 |
| Indicator | AERT | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 43.52 |
| Support Level | $0.53 | $0.65 |
| Resistance Level | $0.65 | $0.72 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 44.29 | 42.38 |
Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.